Literature DB >> 9486984

Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.

K Kato1, M J Cantwell, S Sharma, T J Kipps.   

Abstract

CD40-CD40-ligand (CD154) interactions play a critical role in immune activation. Using replication defective adenovirus encoding mouse CD154 (Ad-CD154), we modified human chronic lymphocytic leukemia B cells to express a functional ligand for CD40. This not only induces expression of immune accessory molecules on the infected cell, but also allows it to trans-activate noninfected bystander leukemia B cells. Also, factors that impair the antigen-presenting capacity of leukemia B cells are downmodulated. Ad-CD154- infected leukemia cells are highly effective stimulators in mixed lymphocyte reactions and can induce generation of cytotoxic T lymphocytes specific for autologous nonmodified leukemia cells. As such, Ad-CD154 can induce a host antileukemia response that may have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486984      PMCID: PMC508665          DOI: 10.1172/JCI1472

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  A cell culture model for T lymphocyte clonal anergy.

Authors:  R H Schwartz
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

2.  Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.

Authors:  E A Clark; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Long-term human B cell lines dependent on interleukin-4 and antibody to CD40.

Authors:  J Banchereau; P de Paoli; A Vallé; E Garcia; F Rousset
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

4.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

5.  Molecular and biological characterization of a murine ligand for CD40.

Authors:  R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

6.  Detection of a novel human class II HLA antigen.

Authors:  A J Watson; R DeMars; I S Trowbridge; F H Bach
Journal:  Nature       Date:  1983 Jul 28-Aug 3       Impact factor: 49.962

7.  Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor.

Authors:  R G Goodwin; M R Alderson; C A Smith; R J Armitage; T VandenBos; R Jerzy; T W Tough; M A Schoenborn; T Davis-Smith; K Hennen
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

8.  S152 (CD27). A modulating disulfide-linked T cell activation antigen.

Authors:  R D Bigler; Y Bushkin; N Chiorazzi
Journal:  J Immunol       Date:  1988-07-01       Impact factor: 5.422

9.  Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation.

Authors:  P Lane; T Brocker; S Hubele; E Padovan; A Lanzavecchia; F McConnell
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

10.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.

Authors:  E A Ranheim; T J Kipps
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  41 in total

1.  Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.

Authors:  J Melo-Cardenas; M Urquiza; T J Kipps; J E Castro
Journal:  Cancer Gene Ther       Date:  2012-03-09       Impact factor: 5.987

2.  Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

Authors:  Januario E Castro; Johanna Melo-Cardenas; Mauricio Urquiza; Juan S Barajas-Gamboa; Ramin S Pakbaz; Thomas J Kipps
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 3.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

4.  Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

5.  EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Helena Schmidtmayerova; Victoria Snarsky; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Leukoc Biol       Date:  2011-05-17       Impact factor: 4.962

6.  Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

Authors:  Claudia Palena; Kenneth A Foon; Dennis Panicali; Alicia Gómez Yafal; Jarasvech Chinsangaram; James W Hodge; Jeffrey Schlom; Kwong Y Tsang
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

Review 7.  Immunotherapy for lymphomas.

Authors:  John M Timmerman
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

8.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.

Authors:  J Ohata; J Sakurai; K Saito; K Tani; S Asano; M Azuma
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

Review 10.  Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.

Authors:  Audrey Mohr; Yves Renaudineau; Cristina Bagacean; Jacques-Olivier Pers; Christophe Jamin; Anne Bordron
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.